Endocrine Function Diagnostics Market Size, Share & Trends Analysis Report By Test Type (TSH, hCG, Insulin), By Technology (Clinical Chemistry, Immunoassay), By Application, By End-use, And Segment Forecasts, 2025 - 2033

Endocrine Function Diagnostics Market Summary

The global endocrine function diagnostics market size was estimated at USD 13.16 billion in 2024 and is projected to reach USD 26.23 billion by 2033, growing at a CAGR of 8.0% from 2025 to 2033. The growing prevalence of endocrine disorders, strong shift towards precision diagnostics, and technological innovations in assays and platforms are some of the major factors contributing to market growth.

According to statistics published by the American Cancer Society, 44,020 new cases of thyroid cancer were reported in the U.S. in 2025. The rate of new thyroid cancers was growing faster compared to other cancers in the U.S. This leads to consistent growth in demand for routine endocrine panel testing in hospitals, clinics, and diagnostic laboratories.

Advancements in product technologies fuel the market demand. According to the Cureus, part of the Springer Nature group, published an article in October 2023, in recent years, remarkable progress has been made in the treatment of endocrine system diseases and arrhythmia. Endocrine system disorders include a variety of diseases such as diabetes, thyroid dysfunction, and adrenal gland disease. Advances in biomarker identification and genomic profiling have made it possible to make more accurate diagnoses and develop individualized treatment plans. In addition, modern drugs and advanced delivery systems represent great progress in achieving improved glycemic control and minimizing the adverse effects of endocrine disorders in individuals characterized by improper heart rhythms. Arrhythmia poses a significant risk to cardiovascular health. Strategies to treat arrhythmia include wearable cardiac monitors, catheter-based ablation techniques, and artificial intelligence-based predictive algorithms. These advances facilitate early detection, risk stratification, and execution of targeted interventions, ultimately leading to improved patient outcomes.

The demand for endocrine function diagnostics is increasing as adults become more health-conscious and the number of lifestyle-related diseases increases. This increased awareness is contributing to the rise of home health care and point-of-care (POC) devices that deliver faster and more efficient results. Home care and POC devices are easy to use and provide a cost-effective alternative for adults and the growing elderly population. The WHO estimates that by 2025, about 167 million people, including adults and children, will be in poor health due to being overweight or obese. The prediction of these diseases is likely to impact the market and result in significant growth during the forecast period.

Increasing health complications in the elderly population are expected to drive the market growth during the forecast period. According to the National Council on Aging article in August 2023, 94.9% of adults aged 60 and older have at least one disease, and 78.7% have two or more. Obesity, which affects about 42% of adults over age 60, can also increase the risk of diseases such as heart disease, type 2 diabetes, and cancer. With the increase in the affected population, the number of tests used in endocrinology has increased substantially. These aspects are expected to boost market growth.

Global Endocrine Function Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global endocrine function diagnostics market report based on test type, technology, end use, application and region:

• Test Type Outlook (Revenue in USD Million, 2021 - 2033)
• Estradiol (E2) Test
• Follicle Stimulating Hormone (FSH) Test
• Human Chorionic Gonadotropin (hCG) Hormone Test
• Luteinizing Hormone (LH) Test
• Dehydroepiandrosterone Sulfate (DHEAS) Test
• Progesterone Test
• Testosterone Test
• Thyroid Stimulating Hormone (TSH) Test
• Prolactin Test
• Cortisol Test
• Insulin Test
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Tandem Mass Spectrometry
• Immunoassay
• Monoclonal & Polyclonal Antibody Technologies
• Sensor Technology
• Clinical Chemistry
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Thyroid Disorders
• Diabetes & Metabolic Disorders
• Adrenal Disorders
• Pituitary Disorders
• Reproductive & Fertility Disorders
• Bone-Mineral Disorders
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Commercial Laboratories
• Ambulatory Care Centers
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• China
• Japan
• India
• Australia
• Thailand
• South Korea
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more